Undisclosed ENPP1 modulator / AN2 Therap - LARVOL DELTA

Advancing ENPP1 candidate for the potential treatment of solid tumors (Businesswire) - "The Company has discovered preclinical compounds that demonstrate sub-nanomolar activity, high selectivity and excellent oral pharmacokinetic properties. Earlier this year, the Company declared a development candidate (ENPP1) for the treatment of solid tumors and expects to advance a second development candidate by the end of 2026."

Pipeline update • Solid Tumor